Therapeutics for Age Related Macular Degeneration

Visgenx is developing therapeutics to protect against the loss of sight  from retinal disorders.  Our programs are based on  modulating a novel gene target which may underlie the loss of retinal cells critical to vision.

THERAPEUTIC FOCUS

Age Related Macular Degeneration / Geographic Atrophy



DEVELOPMENT STRATEGY

Our fast to market approach is based on increasing expression of the target gene by repurposing the de-methylating agent decitabine.  Our longer term goal is gene therapy or an mRNA based therapeutic.